ストックスクリーナーアプリを入手
53.09
3.48%
-1.865
前日終値:
$54.95
開ける：
$54.9
24時間の取引高:
558.56K
Relative Volume:
0.42
時価総額：
$5.44B
収益：
$4.72M
当期純損益:
$-277.91M
株価収益率:
-14.23
EPS:
-3.73
ネットキャッシュフロー:
$-203.56M
1週間 パフォーマンス:
-5.27%
1か月 パフォーマンス:
+8.53%
6か月 パフォーマンス:
+71.21%
1年 パフォーマンス:
+35.31%
1日の値動き範囲:
$52.94
$55.27
1週間の範囲:
$52.94
$56.99
52週間の値動き範囲:
$24.10
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
名前
Crinetics Pharmaceuticals Inc
セクター
電話
858-450-6464
住所
6055 LUSK BLVD., SAN DIEGO, CA
CRNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
53.09 | 5.63B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.16 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.89 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.50 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.90 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.94 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-10 | 開始されました | Goldman | Neutral |
| 2025-03-25 | 開始されました | Stifel | Buy |
| 2025-02-11 | 開始されました | TD Cowen | Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Peer Perform |
| 2025-01-22 | アップグレード | Jefferies | Hold → Buy |
| 2024-03-06 | 開始されました | Citigroup | Buy |
| 2024-01-16 | 開始されました | Morgan Stanley | Overweight |
| 2023-12-21 | 開始されました | Jefferies | Hold |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 開始されました | Oppenheimer | Outperform |
| 2023-04-24 | 開始されました | Piper Sandler | Overweight |
| 2023-03-30 | 開始されました | Robert W. Baird | Outperform |
| 2021-11-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-11-23 | 開始されました | Evercore ISI | Outperform |
| 2021-06-18 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 開始されました | ROTH Capital | Buy |
| 2019-02-14 | 開始されました | H.C. Wainwright | Buy |
| 2018-08-13 | 開始されました | JP Morgan | Neutral |
| 2018-08-13 | 開始されました | Leerink Partners | Outperform |
| 2018-08-13 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Crinetics Pharmaceuticals Inc (CRNX) 最新ニュース
Crinetics begins phase 2/3 trial of oral CAH treatment in children - Investing.com Nigeria
Crinetics (CRNX) Launches Phase 2/3 Trial for Atumelnant in Pedi - GuruFocus
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) - GlobeNewswire
Jim Cramer on Crinetics: “That’s a Better Spec Than Aquestive” - Insider Monkey
Goldman Sachs upgrades Crinetics Pharmaceuticals, Inc. (CRNX) to buy from neutral - MSN
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Goldman Sachs Upgrade And Palsonify Atumelnant Progress - Sahm
Retail Surge: What is the dividend yield of Crinetics Pharmaceuticals Inc2025 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Crinetics Pharmaceuticals exec sells shares worth $195,350 - MSN
Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral - Insider Monkey
Hedge Fund Bets: Can Crinetics Pharmaceuticals Inc be recession proofEarnings Risk Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Why Crinetics Pharmaceuticals (CRNX) Is Up 18.2% After Equity Raise and PALSONIFY, Atumelnant Updates - Sahm
Crinetics Pharmaceuticals discovers new SSTR2 non-peptide-drug conjugates - BioWorld MedTech
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Goldman Sachs Upgrades Crinetics Pharmaceuticals (CRNX) - Nasdaq
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CRNX Upgraded to 'Buy' by Goldman Sachs with New Price Target of $67 | CRNX Stock News - GuruFocus
Crinetics Shares Rise After Goldman Sachs Upgrade - marketscreener.com
The Goldman Sachs Group Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy - MarketBeat
Crinetics stock rating upgraded by Goldman Sachs on promising CAH drug data - Investing.com Canada
10 new Crinetics workers get stock awards vesting over 4 years - Stock Titan
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
How Crinetics Pharmaceuticals Inc. stock trades during market volatility2025 Earnings Surprises & Weekly High Return Stock Opportunities - Улправда
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Crinetics Pharmaceuticals prices offering at $45.95 per share - MSN
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Strong Share Price Momentum - Sahm
What risks investors should watch in Crinetics Pharmaceuticals Inc. stockLong Setup & Safe Capital Investment Plans - Улправда
Is Crinetics Pharmaceuticals Inc. stock overvalued by current metricsWeekly Trend Report & High Conviction Trade Alerts - Улправда
Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersTrade Volume Summary & Technical Pattern Alert System - ulpravda.ru
Gains Report: Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersJuly 2025 Spike Watch & Safe Capital Preservation Plans - ulpravda.ru
Analyst Calls: How risky is Crinetics Pharmaceuticals Inc. stock nowJuly 2025 Outlook & Risk Controlled Stock Pick Alerts - Улправда
Citizens Jmp Has Lowered Expectations for Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price - MarketBeat
Crinetics Pharmaceuticals (CRNX): Analyst Updates on Price Targe - GuruFocus
Crinetics stock price target lowered to $105 by Citizens on endocrinologist survey - Investing.com UK
Crinetics Pharmaceuticals prices public offering at $45.95 per share By Investing.com - Investing.com Nigeria
US Market Wrap: Will Crinetics Pharmaceuticals Inc 6Z4 stock issue positive guidance2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Crinetics (CRNX) Sees Significant Stock Price Increase - GuruFocus
Crinetics Pharma CCO Kalofonos sells $137,500 in shares By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals’ Positive Trial Results and Stock Target Uplift Spark Optimism - StocksToTrade
Crinetics Announces Major Public Offering to Fund Growth - TipRanks
Crinetics’ Stocks Surge: Promising Future or Mirage? - timothysykes.com
Crinetics Pharmaceuticals Announces Public Offering of Common Stock - TradingView — Track All Markets
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
Crinetics Shares Rise After Pricing $350 Million Stock Offering - marketscreener.com
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial - Asianet Newsable
Crinetics Pharmaceuticals’ Stock Surges after Positive Trial Results and Analyst Boosts - timothysykes.com
Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits - TechStock²
Crinetics (CRNX) Stock Soars Over 12% Amid Market Activity - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up Following Analyst Upgrade - MarketBeat
Why Crinetics Pharmaceuticals Shares Are Sinking Today - TipRanks
Crinetics Pharma climbs after $350 mln stock sale - TradingView — Track All Markets
Crinetics Pharmaceuticals Inc (CRNX) 財務データ
収益
当期純利益
現金流量
EPS
3.31%
2.05%
大文字化:
|
ボリューム (24 時間):